Work

Emerging innovations in theranostics for pancreatic neuroendocrine tumors

Year: 2025

Type: review

Abstract: Pancreatic neuroendocrine tumors (pNETs) often overexpress somatostatin receptor type 2 (SSTR2), making them ideal targets for theranostics, which integrates molecular imaging with targeted radionuclide therapy. 177 Lu-DOTATATE significantly extends progression-free survival (22.8 vs. 8.5 months) compared to octreotide LAR. Despite these advances, challenges remain, including treatment resistance and long-term toxicities. In this review, we explore advancements in specialized imaging techniques, rationale combination strategies, and exploring next-generation radiopharmaceuticals.

Source: npj Precision Oncology

DOI: 10.1038/s41698-025-00938-1

Authors: Anita Karimi, Christina Bogdani, Elisabeth O’Dwyer, Despina Siolas

Institutions: Weill Cornell Medicine, New York Institute of Technology

Language: English

Topic: Neuroendocrine Tumor Research Advances

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,090